Tumor cells deficient in BRCA1 or RAD51, or those with compromised DNA repair mechanisms, cannot effectively repair DNA damage and thus show heightened sensitivity to platinum-based chemotherapeutic agents. The gene discussed is RAD51; the disease is neoplasm.